DBVT Insider Transactions
Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
---|---|---|---|---|---|---|---|---|
2024-03-08 | Tasse Daniel | director, officer: CHIEF EXECUTIVE OFFICER | 17,094 | P-Purchase | A | 17,094 | 0.83 | 14,188.00 |
2024-02-06 | Ndu Adora | director | 1,825 | P-Purchase | A | 1,825 | 0.89 | 1,624.00 |
2023-11-22 | Mohideen Pharis | officer: Chief Medical Officer | 82,194 | S-Sale | D | 2,245 | 1.74 | 3,906.00 |
2023-11-20 | Boucinha Virginie | officer: Chief Financial Officer | 113,000 | A-Award | A | 113,000 | 2.19 | 247,470.00 |
2023-11-20 | Boucinha Virginie | officer: Chief Financial Officer | 19,000 | A-Award | A | 19,000 | 0.00 | 0.00 |
2023-11-20 | Tasse Daniel | director, officer: Chief Executive Officer | 806,672 | A-Award | A | 806,672 | 2.19 | 1,766,612.00 |
2023-11-20 | Mohideen Pharis | officer: Chief Medical Officer | 215,000 | A-Award | A | 215,000 | 2.19 | 470,850.00 |
2023-11-20 | Mohideen Pharis | officer: Chief Medical Officer | 84,439 | A-Award | A | 35,000 | 0.00 | 0.00 |
2023-11-06 | Boucinha Virginie | officer | 0 | 0 | 0.00 | 0.00 | ||
2023-08-25 | MORRIS TIMOTHY E | director | 12,000 | P-Purchase | A | 12,000 | 1.52 | 18,240.00 |
2022-11-21 | Tasse Daniel | director, officer: Chief Executive Officer | 764,386 | A-Award | A | 764,386 | 3.07 | 2,346,665.00 |
2022-11-21 | Mohideen Pharis | officer: Chief Medical Officer | 115,000 | A-Award | A | 115,000 | 3.07 | 353,050.00 |
2022-07-29 | Mohideen Pharis | officer: Chief Medical Officer | 100,000 | A-Award | A | 100,000 | 4.83 | 483,000.00 |
2022-11-21 | Mohideen Pharis | officer: Chief Medical Officer | 51,700 | A-Award | A | 17,500 | 0.00 | 0.00 |
2022-11-24 | Mohideen Pharis | officer: Chief Medical Officer | 49,908 | S-Sale | D | 1,792 | 2.88 | 5,161.00 |
2023-05-24 | Mohideen Pharis | officer: Chief Medical Officer | 49,439 | S-Sale | D | 469 | 3.54 | 1,660.00 |
2022-07-29 | Mohideen Pharis | officer: Chief Medical Officer | 34,200 | A-Award | A | 10,000 | 0.00 | 0.00 |
2022-11-21 | Robitaille Sebastien | officer: Chief Financial Officer | 65,000 | A-Award | A | 65,000 | 3.07 | 199,550.00 |
2022-11-21 | Robitaille Sebastien | officer: Chief Financial Officer | 36,500 | A-Award | A | 8,000 | 0.00 | 0.00 |
2023-08-01 | SOLAND DANIEL B | director | 20,000 | P-Purchase | A | 15,000 | 1.62 | 24,300.00 |
2022-10-03 | Guyot-Caparros Daniele | director: | 0 | 0 | 0.00 | 0.00 | ||
2022-06-13 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 14,575,984 | A-Award | A | 10,622,568 | 0.00 | 0.00 |
2022-06-13 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 11,732,979 | A-Award | A | 11,732,979 | 0.00 | 0.00 |
2022-06-13 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 1,585,054 | A-Award | A | 1,252,432 | 0.00 | 0.00 |
2022-06-13 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 1,383,352 | A-Award | A | 1,383,352 | 0.00 | 0.00 |
2022-06-13 | Baker Brothers Life Sciences LP | director: | 1,383,352 | A-Award | A | 1,383,352 | 0.00 | 0.00 |
2021-11-22 | Tasse Daniel | director, officer: Chief Executive Officer | 274,000 | A-Award | A | 274,000 | 6.62 | 1,813,880.00 |
2021-11-22 | Mohideen Pharis | officer: Chief Medical Officer | 95,400 | A-Award | A | 95,400 | 6.62 | 631,548.00 |
2021-11-22 | Mohideen Pharis | officer: Chief Medical Officer | 24,200 | A-Award | A | 8,700 | 0.00 | 0.00 |
2021-11-22 | Robitaille Sebastien | officer: Chief Financial Officer | 51,000 | A-Award | A | 51,000 | 6.62 | 337,620.00 |
2021-11-22 | Robitaille Sebastien | officer: Chief Financial Officer | 28,500 | A-Award | A | 5,000 | 0.00 | 0.00 |
2021-06-10 | SOLAND DANIEL B | director | 6,837 | P-Purchase | A | 6,837 | 13.09 | 89,496.00 |
2021-06-10 | Ndu Adora | director | 6,837 | P-Purchase | A | 6,837 | 13.09 | 89,496.00 |
2021-06-10 | MORRIS TIMOTHY E | director | 6,837 | P-Purchase | A | 6,837 | 13.09 | 89,496.00 |
2021-06-10 | Monges Viviane | director | 5,000 | P-Purchase | A | 5,000 | 13.09 | 65,450.00 |
2021-06-10 | DE ROSEN MICHEL | director | 6,837 | P-Purchase | A | 6,837 | 13.09 | 89,496.00 |
2021-06-10 | Rao Madduri Ravin | director | 6,837 | P-Purchase | A | 6,837 | 13.09 | 89,496.00 |
2021-05-19 | Rao Madduri Ravin | director: | 0 | 0 | 0.00 | 0.00 | ||
2021-05-19 | Ndu Adora | director: | 0 | 0 | 0.00 | 0.00 | ||
2021-03-30 | MORRIS TIMOTHY E | director: | 0 | 0 | 0.00 | 0.00 | ||
2021-01-01 | DE ROSEN MICHEL | director | 23,570 | D | 0 | 0.00 | 0.00 | |
2018-06-28 | DE ROSEN MICHEL | director | 0 | D | 9,000 | 45.54 | 409,860.00 | |
2021-01-01 | GOLLER MICHAEL | director: | 0 | 0 | 0.00 | 0.00 | ||
2021-01-01 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 13,413,895 | I | 0 | 0.00 | 0.00 | |
2021-01-01 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 3,953,416 | I | 0 | 0.00 | 0.00 | |
2021-01-01 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 1,200,369 | I | 0 | 0.00 | 0.00 | |
2021-01-01 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 332,622 | I | 0 | 0.00 | 0.00 | |
2021-01-01 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | 0 | I | 7,000 | 0.00 | 0.00 | |
2021-01-01 | Tasse Daniel | director, officer: Chief Executive Officer | 0 | D | 350,000 | 36.71 | 12,848,500.00 | |
2021-01-01 | Tasse Daniel | director, officer: Chief Executive Officer | 0 | D | 150,000 | 20.78 | 3,117,000.00 | |
2021-01-01 | Tasse Daniel | director, officer: Chief Executive Officer | 0 | D | 274,000 | 5.09 | 1,394,660.00 | |
2021-01-01 | SOLAND DANIEL B | director | 5,000 | D | 0 | 0.00 | 0.00 | |
2018-05-16 | SOLAND DANIEL B | director | 0 | D | 7,000 | 45.54 | 318,780.00 | |
2015-03-24 | SOLAND DANIEL B | director | 0 | D | 10,000 | 52.59 | 525,900.00 | |
2015-11-19 | SOLAND DANIEL B | director | 0 | D | 7,500 | 80.79 | 605,925.00 | |
2016-12-09 | SOLAND DANIEL B | director | 0 | D | 7,000 | 85.30 | 597,100.00 | |
2021-01-01 | Robitaille Sebastien | officer: Chief Financial Officer | 23,500 | D | 0 | 0.00 | 0.00 | |
2021-01-01 | Robitaille Sebastien | officer: Chief Financial Officer | 0 | D | 51,000 | 5.09 | 259,590.00 | |
2017-06-15 | O'Neill Julie | director | 0 | D | 9,000 | 72.22 | 649,980.00 | |
2018-02-07 | O'Neill Julie | director | 0 | D | 7,000 | 45.54 | 318,780.00 | |
2021-01-01 | Monges Viviane | director | 600 | D | 0 | 0.00 | 0.00 | |
2021-01-01 | Mohideen Pharis | officer: Chief Medical Officer | 15,500 | D | 0 | 0.00 | 0.00 | |
2021-01-01 | Mohideen Pharis | officer: Chief Medical Officer | 0 | D | 75,000 | 21.89 | 1,641,750.00 | |
2021-01-01 | Mohideen Pharis | officer: Chief Medical Officer | 0 | D | 95,400 | 5.09 | 485,586.00 | |
2016-06-12 | Giraut Claire | director | 0 | D | 10,000 | 64.78 | 647,800.00 | |
2018-06-26 | Giraut Claire | director | 0 | D | 7,000 | 45.54 | 318,780.00 | |
2021-01-01 | Ferrere Mailys | director: | 0 | 0 | 0.00 | 0.00 | ||
2021-01-01 | Bjerke Torbjorn | director | 35,925 | D | 0 | 0.00 | 0.00 | |
2018-06-26 | Bjerke Torbjorn | director | 0 | D | 7,000 | 45.54 | 318,780.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.